Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $19
Portfolio Pulse from jenniferd'souza@benzinga.com
Mizuho analyst Vamil Divan has maintained a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and lowered the price target from $45 to $19.
August 08, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mizuho has maintained a Neutral rating on Sage Therapeutics and lowered the price target from $45 to $19.
The lowering of the price target by Mizuho from $45 to $19 indicates a negative outlook for Sage Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100